History of prophylaxis

Haemophilia

Volumn 19, Issue 2, 2013, Pages 163-165

  Berntorp, E ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9;

ARTHROPATHY; ARTICLE; BLEEDING; COST EFFECTIVENESS ANALYSIS; FOLLOW UP; HEMOPHILIA; HUMAN; NETHERLANDS; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; PRIMARY PREVENTION; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

COAGULANTS; FACTOR IX; FACTOR VIII; HEMOPHILIA A; HEMOPHILIA B; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS;

EID: 84874028913     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12100     Document Type: Article

References (40)

1. Forbes CD. The early history of hemophilia. In: Forbes CD, Aledort L, Madhok R eds. Hemophilia. London: Chapman & Hall, 1997: 3-6.
2. Biggs R, Douglas AS, Macfarlane RG, Dacie JV, Pitney WR, Merskey Christmas disease: a condition previously mistaken for haemophilia. Br Med J 1952; 2: 1378-82.
3. Blombäck B. Studies on fibrinogen and antihaemophilic globulin, XIIth Conference of the Protein Foundation on blood cells and plasma proteins, Albany, NY, November 1957. Vox Sang 1958; 3: 58.
4. Blombäck B. A journey with bleeding time factor. Compr Biochem 2007; 45: 209-55.
5. Nilsson IM, Blombäck B, von Francken I. On an inherited autosomal hemorrhagic diathesis with antihemophilic globulin (AHG) deficiency and prolonged bleeding time. Acta Med Scand 1957; 159: 35-57.
6. Pool JG. Cryoprecipitate in the treatment of hemophilia. Calif Med 1970; 113: 66-7.
7. Nilsson IM, Ahlberg A, Bjorlin G. Clinical experience with a Swedish factor IX concentrate. Acta Med Scand 1971; 190: 257-66.
8. Ramgren O. Haemophilia in Sweden. III. Symptomatology, with special reference to differences between haemophilia A and B. Acta Med Scand 1962; 171: 237-42.
9. Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand Suppl 1965; 77(Suppl): 3-132.
10. Van Creveld S. Prophylaxis of joint hemorrhages in hemophilia. Acta Haematol 1969; 41: 206-14.
11. van Creveld S. Prophylaxis in haemophilia. Lancet 1971; 1: 450.
12. Robinson PM, Tittley P, Smiley RK. Prophylactic therapy in classical hemophilia: a preliminary report. Can Med Assoc J 1967; 97: 559-61.
13. Hirschman RJ, Itscoitz SB, Shulman NR. Prophylactic treatment of factor VIII deficiency. Blood 1970; 35: 189-94.
14. Kasper CK, Dietrich SL, Rapaport SI. Hemophilia prophylaxis with factor VIII concentrate. Arch Intern Med 1970; 125: 1004-9.
15. Aronstam A, Arblaster PG, Rainsford SG et al. Prophylaxis in haemophilia: a double-blind controlled trial. Br J Haematol 1976; 33: 81-90.
16. Schimpf K, Fischer B, Rothmann P. [A controlled study of treating haemophilia A on an out-patient basis (author's transl)]. Dtsch Med Wochenschr 1976; 101: 141-8.
17. Morfini M, Mannucci PM, Mariani G et al. Evaluation of prophylactic replacement therapy in haemophilia B. Scand J Haematol 1976; 16: 41-7.
18. Ramsay DM, Parker AC. A trial of prophylactic replacement therapy in haemophilia and Christmas disease. J Clin Pathol 1973; 26: 243-7.
19. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
20. Gilbert MS. Prophylaxis: Musculoskeletal evaluation. Semin Hematol 1993; 30: 3-6.
21. Pettersson H, Ahlberg A, Nilsson IM. A radiologic classification of hemophilic arthropathy. Clin Orthop Relat Res 1980; 149: 153-9.
22. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994; 236: 391-9.
23. Steen Carlsson K, Hojgard S, Glomstein A et al. On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome. Haemophilia 2003; 9: 555-66.
24. Steen Carlsson K, Astermark J, Donfield S, Berntorp E. Cost and outcome: comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitor. Thromb Haemost 2008; 99: 1060-7.
25. Fischer K, van der Bom JG, Molho P et al. Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia 2002; 8: 745-52.
26. Berntorp E, Astermark J, Baghaei F et al. Treatment of haemophilia A and B and von Willebrand's disease: summary and conclusions of a systematic review as part of a Swedish health-technology assessment. Haemophilia 2012; 18: 158-65.
27. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
28. Gringeri A, Lundin B, Von Mackensen S, Mantovani L, Mannucci PM. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9: 700-10.
29. Berntorp E, Fischer K, Miners A. Models of prophylaxis. Haemophilia 2012; 18(Suppl. 4): 136-40.
30. Feldman BM, Pai M, Rivard GE et al. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006; 4: 1228-36.
31. Petrini P, Lindvall N, Egberg N, Blomback M. Prophylaxis with factor concentrates in preventing hemophilic arthropathy. Am J Pediatr Hematol Oncol 1991; 13: 280-7.
32. Astermark J, Petrini P, Tengborn L, Schulman S, Ljung R, Berntorp E. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999; 105: 1109-13.
33. Doria AS. State-of-the-art imaging techniques for the evaluation of haemophilic arthropathy: present and future. Haemophilia 2010; 16(Suppl. 5): 107-14.
34. Lundin B, Babyn P, Doria AS et al. Compatible scales for progressive and additive MRI assessments of haemophilic arthropathy. Haemophilia 2005; 11: 109-15.
35. Feldman BM, Aledort L, Bullinger M et al. The economics of haemophilia prophylaxis: governmental and insurer perspectives. Proceedings of the Second International Prophylaxis Study Group (IPSG) symposium. Haemophilia 2007; 13: 745-9.
36. Carlsson M, Berntorp E, Bjorkman S, Lindvall K. Pharmacokinetic dosing in prophylactic treatment of hemophilia A. Eur J Haematol 1993; 51: 247-52.
37. Carlsson M, Bjorkman S, Berntorp E. Multidose pharmacokinetics of factor IX: implications for dosing in prophylaxis. Haemophilia 1998; 4: 83-8.
38. Lindvall K, Astermark J, Bjorkman S et al. Daily dosing prophylaxis for haemophilia: a randomized crossover pilot study evaluating feasibility and efficacy. Haemophilia 2012; 18: 855-9.
39. Bjorkman S, Collins P. The Project on Factor VIII/factor IX PK of The FVIII/factor IX Scientific Standardisation Committee of the International Society on Thrombosis Haemostasis. Measurement of factor VIII pharmacokinetics in routine clinical practice. J Thromb Haemost 2012; 19 December 2012 [Epub ahead of print]. doi:10.1111/jth.12055.
40. Collins PW. Personalized prophylaxis. Haemophilia 2012; 18(Suppl. 4): 131-5.